<DOC>
	<DOCNO>NCT00002744</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug give different way may kill cancer cell . It yet know regimen combination chemotherapy effective acute lymphoblastic leukemia PURPOSE : Randomized phase III trial compare different regimens combination chemotherapy treat child newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : I . Identify response relate factor predictive relapse among child previously untreated standard risk acute lymphoblastic leukemia ( ALL ) . II . Determine prognostic significance residual leukemic blast specific time induction therapy : M3 marrow status ( great 25 % blast ) day 7 ; M2 status ( 5 % -25 % blast ) day 14 ; residual circulating leukemic blast day 7 14 . III . Determine prognostic significance residual leukemic burden , measure fluorescence activate cell sorting/leukemic progenitor cell assay , marrow aspirate acquire end induction therapy , begin maintenance therapy , completion therapy patient B precursor ALL . IV . Determine prognostic significance residual ( 1 ; 19 ) detect marrow aspirate PCR-based analysis fusion transcript E2A-PBX1 end induction therapy , begin maintenance therapy , completion therapy . V. Examine interrelationships among response-related prognostic factor correlation ploidy , karyotype , immunophenotype . VI . Determine , randomize study , whether substitution oral thioguanine ( TG ) oral mercaptopurine ( MP ) consolidation , interim maintenance , maintenance therapy improve event-free survival patient standard-risk ALL . VII . Study compare cellular pharmacokinetics oral MP oral TG interim maintenance maintenance therapy select patient . VIII . Compare concentration MP TG red blood cell metabolite ( i.e. , nucleotide , nucleoside , free base , methylated metabolite ) interim maintenance maintenance therapy , determine whether low level metabolites predict relapse select patient . IX . Determine activity thiopurine methyltransferase hypoxanthine guanine phosphoribosyl transferase several time interim maintenance maintenance treatment , compare activity two thiopurine treatment group select patient . X . Compare incidence central nervous system ( CNS ) relapse event-free survival patient receive intrathecal methotrexate ( MTX ) vs. triple intrathecal chemotherapy ( MTX/cytarabine/hydrocortisone ) presymptomatic CNS treatment . XI . Determine whether cerebrospinal fluid ( CSF ) terminal deoxynucleotidyl transferase ( TdT ) positivity predict CNS marrow relapse measure TdT activity CSF cytospins case low white blood cell count ( le 5 cell per cubic millimeter ) suspect questionable `` blast '' maintenance therapy . XII . Determine event-free survival patient standard-risk ALL M3 marrow day 14 treat intensive therapy design higher-risk ALL . OUTLINE : This randomize study . Patients stratify accord participate institution . The following acronym use : ARA-C Cytarabine , NSC-63878 ASP Asparaginase ( E. coli ) , NSC-109229 CTX Cyclophosphamide , NSC-26271 DM Dexamethasone , NSC-34521 DNR Daunorubicin , NSC-82151 DOX Doxorubicin , NSC-123127 HC Hydrocortisone , NSC-10483 MP Mercaptopurine , NSC-755 MTX Methotrexate , NSC-740 PEG-ASP Pegaspargase , NSC-624239 PRED Prednisone , NSC-10023 TG Thioguanine , NSC-752 TIT Triple Intrathecal Therapy ( IT MTX/IT ARA-C/IT HC ) VCR Vincristine , NSC-67574 Induction : All patient receive oral PRED day 0-27 , VCR IV day 0 , 7 , 14 , 21 , ASP IM 3 time week 3 week begin day 2-4 . ARA-C IT administer day 0 , MTX IT administer day 7 28 ( day 7 , 14 , 21 , 28 CNS disease diagnosis ) . Following Induction , patient achieve remission randomly assign 1 4 treatment arm . Arm I : Consolidation ( begin day 28 Induction ) : PRED taper Induction 10 day . Patients receive VCR IV day 0 , oral MP day 1-27 , MTX IT day 7 , 14 , 21 ( day 7 CNS disease diagnosis ) . Interim Maintenance 1 ( begin day 28 Consolidation ) : Patients receive oral PRED day 0-4 28-32 , VCR IV day 0 28 , oral MTX day 0 , 7 , 14 , 21 , 28 , 35 , 42 , 49 , oral MP day 0-49 . Delayed Intensification 1 ( begin day 56 Interim Maintenance 1 ) : Patients receive oral DM day 0-6 14-20 , VCR IV day 0 , 7 , 14 , DOX IV 15-120 min day 0 , 7 , 14 , ASP IM twice week 2 week begin day 2-4 , CTX IV 20-30 min day 28 , oral TG day 28-41 , ARA-C IV SC day 29-32 36-39 , MTX IT day 0 , 28 , 35 . Interim Maintenance 2 ( begin day 56 Delayed Intensification 1 ) : Patients receive PRED/VCR/MTX/MP Interim Maintenance 1 . Delayed Intensification 2 ( begin day 56 Interim Maintenance 2 ) : Patients receive DM/VCR/DOX/ASP , CTX/TG/ARA-C , MTX IT Delayed Intensification 1 . Maintenance ( begin day 56 Delayed Intensification 2 ) : Patients receive oral PRED day 0-4 , 28-32 , 56-60 , VCR IV day 0 , 28 , 56 , oral MP day 0-83 , oral MTX day 7 , 14 , 21 , 28 , 35 , 42 , 49 , 56 , 63 , 70 , 77 ( omit wk IT therapy ) , MTX IT day 0 . Treatment continue every 84 day 2 year ( girl ) 3 year ( boy ) begin Interim Maintenance 1 . Arm II : Patients receive treatment arm I , except TIT TIT substitute MTX IT . Arm III : Patients receive treatment arm I oral TG substitute oral MTX Consolidation , Interim Maintenance 1 2 , Maintenance . If secondary veno-occlusive disease occur , MP substitute TG Maintenance . Arm IV : Patients receive treatment arm III TIT substitute MTX IT . If secondary veno-occlusive disease occur , MP substitute TG Maintenance . Patients M3 marrow 2 week M2 marrow 4 week Induction , Philadelphia chromosome ( [ 9 ; 22 ] [ q34 ; q11 ] ) , ( 4 ; 11 ) ( q21 ; q23 ) , hypodiploidy , proceed follow intensive treatment regimen therapy : Induction ( begin day 14 day 19 initial Induction ) : Patients receive oral PRED day 14-27 , VCR IV day 14 21 ( day 14 dose omit day 14 dose original Induction already give ) , DNR IV continuously day 14-16 ( 48 hour total ) , ASP IM three time week 9 total dos ( include receive original Induction ) , MTX IT day 28 35 ( day 21 , 28 , 35 CNS disease diagnosis ) . Patients M1/M2 bone marrow day 35 proceed Consolidation . Consolidation ( begin day 28 35 Induction regimen , depend time entry regimen ) : PRED taper Induction 10 day . Patients receive CTX IV 20-30 minute day 0 28 , oral MP day 0-13 28-41 , ARA-C IV SC day 1-4 , 8-11 , 29-32 , 36-39 , VCR IV day 14 , 21 , 42 , 49 , PEG-ASP IM day 14 42 , MTX IT day 7 , 14 , 21 ( day 7 CNS disease diagnosis ) . Patients M1 M2 marrow extramedullary leukemia day 63 proceed Interim Maintenance 1 . Interim Maintenance 1 ( begin day 63 Consolidation ) : Patients receive VCR IV day 0 , 10 , 20 , 30 , 40 , MTX IV day 0 , 10 , 20 , 30 , 40 , PEG-ASP IM day 1 21 . Patients M1 bone marrow day 56 proceed Delayed Intensification I . Delayed Intensification 1 ( begin day 56 Interim Maintenance 1 ) : Patients receive oral DM day 0-6 14-20 , VCR IV day 0 , 7 , 14 , 42 , 49 , DOX IV 15-120 minute day 0 , 7 , 14 , PEG-ASP IM day 3 42 , CTX IV 20-30 minute day 28 , oral TG day 28-41 , ARA-C IV SC day 29-32 36-39 , MTX IT day 28 35 . Interim Maintenance 2 ( begin day 56 Delayed Intensification 1 ) : Patients receive VCR/MTX/PEG-ASP Interim Maintenance 1 , MTX IT day 0 , 20 , 40 . Delayed Intensification 2 ( begin day 56 Interim Maintenance 2 ) : Patients receive DM/VCR/DOX/PEG-ASP , CTX/TG/ARA-C , MTX IT Delayed Intensification 1 . Maintenance ( begin day 56 Delayed Intensification 2 ) : Patients receive PRED/VCR/MP/MTX , MTX IT arm I Maintenance . Patients CNS testicular involvement diagnosis receive appropriate radiotherapy concurrent Consolidation . Radiotherapy begin within 4 day initiation Consolidation . Craniospinal irradiation give 5 day week . Testicular irradiation give testes 5 day week 2-3 week . Patients follow every 6-8 week year 1 , every 3 month year 2 , every 6 month year 3 , annually thereafter . PROJECTED ACCRUAL : A total 1970 patient accrue study within 3.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
	<mesh_term>Cortisol succinate</mesh_term>
	<mesh_term>Hydrocortisone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Hydrocortisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pegaspargase</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute lymphoblastic leukemia ( ALL ) obtain bone marrow aspirate bone marrow biopsy No great 25 % L3 blast Initial white blood cell count le 50,000/mm3 ( perform CCG institution ) Massive lymphadenopathy , massive splenomegaly , and/or large mediastinal mass allow CNS testicular leukemia allow Allogeneic bone marrow transplant consider ( donor available ) patient Philadelphia chromosome ( [ 9 ; 22 ] [ q34 ; q11 ] ) translocation ( 4 ; 11 ) ( q21 ; q23 ) PATIENT CHARACTERISTICS : Age : 1 9 Performance status : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : No prior treatment ALL Biologic therapy : Not specify Chemotherapy : Intrathecal cytarabine ( IT ARAC ) may begin prior registration provide systemic chemotherapy initiate within 72 hour IT ARAC Endocrine therapy : See Radiotherapy At least 1 month since prior systemic steroid Steroids give less 48 hour allow Inhaled corticosteroid allow time Radiotherapy : Radiotherapy dexamethasone mediastinal mass cause superior mediastinal syndrome allow prior registration , indicate Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>L1 childhood acute lymphoblastic leukemia</keyword>
	<keyword>L2 childhood acute lymphoblastic leukemia</keyword>
</DOC>